Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeut...
Gespeichert in:
Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2020-11, Vol.220, p.108598-108598, Article 108598 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!